Baldwin Investment Management’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
Other funds holding HQL
Baldwin Investment Management's HQL Position: Q3 2026 in Review
Baldwin Investment Management increased its abrdn Life Sciences Investors (HQL) stake by 3.2% in Q3 2026, buying an estimated $6.68K and bringing the position to 10,741 shares worth $201K. The position accounts for 0.02% of the portfolio, ranked #241.
Baldwin Investment Management first reported a position in HQL in Q1 2026 and has held it in 3 quarters since. The position peaked at $208K in Q2 2026. 83 funds tracked by Wall St. Rank hold HQL as of Q3 2026.
- Baldwin Investment Management held 10,741 shares of abrdn Life Sciences Investors worth $201K as of Q3 2026.
- Baldwin Investment Management bought 330 abrdn Life Sciences Investors shares in Q3 2026, an estimated $6.68K.
- abrdn Life Sciences Investors made up 0.02% of Baldwin Investment Management's portfolio in Q3 2026, its #241 holding.
- Baldwin Investment Management first reported a position in abrdn Life Sciences Investors in Q1 2026 and has held it in 3 quarters since.
- Baldwin Investment Management's abrdn Life Sciences Investors position peaked at $208K in Q2 2026.
- 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.
Based on Baldwin Investment Management's 13F filing for Q3 2026, filed 13 Nov 2026.